SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
June 24, 2021
(Exact Name of Registrant as Specified in Charter)
|(State or Other Jurisdiction|
400 Technology Square, 4th Floor
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: (617) 229-5872
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
|Common stock, $0.0001 par value||EPZM||Nasdaq Global Select Market|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 24, 2021, Paolo Tombesi, the Chief Financial Officer of Epizyme, Inc., a Delaware corporation (the “Company”), notified the Company that he will be leaving the Company to pursue other business opportunities, effective July 16, 2021.
The Company’s finance function will continue to report to Robert B. Bazemore, the Company’s President and Chief Executive Officer. Matthew E. Ros, the Company’s Executive Vice President, Chief Strategy and Business Officer, will serve as the Company’s principal financial officer, effective July 16, 2021, a role that Mr. Ros has previously served at the Company.
Mr. Ros, 55, has served as the Company’s Executive Vice President, Chief Strategy and Business Officer since September 2020, served as the Company’s Chief Strategy and Business Officer from September 2018 to September 2020 and served as the Company’s Chief Operating Officer from May 2016 to September 2018. Mr. Ros has also served as a member of the board of directors of Cogent Biosciences, Inc., a publicly traded biotechnology company, since July 2019.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 28, 2021||By:|
/s/ Robert B. Bazemore
|Robert B. Bazemore|
|President and Chief Executive Officer|